Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome March 25, 2026 12:30 PM EDT
Company Participants
Laura Hansen
Ryan Watts – Co-Founder, President, CEO & Director
Peter Chin – Acting Chief Medical Officer & Head of Development
Katie Peng – Chief Commercial Officer
Alexander Schuth – Co-Founder, CFO, COO & Secretary
Conference Call Participants
Lin Tsai – Jefferies LLC, Research Division
Michael Yee – UBS Investment Bank, Research Division
Michael Riad – Morgan Stanley, Research Division
Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Laura Chico – Wedbush Securities Inc., Research Division
John Peyton Bohnsack – TD Cowen, Research Division
John Boyle – William Blair & Company L.L.C., Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Presentation
Operator
Thank you for standing by, and welcome to the AVLAYAH FDA Approval Call. [Operator Instructions] As a reminder, today’s program is being recorded. And now I’d like to introduce your host for today’s program, Laura Hansen, Vice President of Investor Relations. Please go ahead.
Laura Hansen
Thank you, Jonathan, and good day, everyone. Thank you for joining us today for our AVLAYAH FDA Approval Conference Call. I’m Laura Hansen, Vice President of Investor Relations at Denali Therapeutics. Joining me on the call today are Ryan Watts, Chief Executive Officer; Alexander Schuth, Chief Financial and Operating Officer; Peter Chin, Chief Medical Officer; and Katie Peng, Chief Commercial Officer. Earlier today, we issued a press release announcing the FDA approval of AVLAYAH. The press release and the slide presentation to accompany today’s call are available in the Investor Relations section of our website at denalitherapeutics.com.
Before we begin, I’d like to remind you that today’s call will contain forward-looking statements within the meaning
Read the full article here
